13:30-13:50　Cross-Border BD Transactions: Lessons Learned and Best Practices
Gerry Zhao: Partner, JunHe LLP

13:50-14:05　From License-out to Evidence-Ready: The Next Phase of Global Business Development for Chinese Innovative Biopharma
Erdong Cheng: Managing Director, Custom Solutions, APAC Norstella

14:05-14:20　Statistics-Driven Global Business Development
Zhenming Xun: Former Global Head of Biostatistics and Data Management, Daiichi Sankyo

14:20-14:35　Tax Considerations for Cross-Border BD Transactions and Overseas Investment in Innovative Biopharma
TBD, Ernst & Young

14:35-14:50　Intellectual Property Considerations for Collaborations with U.S. Pharmaceutical Companies
Yieyie Yang: Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

14:50-15:05　Deepen Cross-border Financial Services to Fully Support Enterprises in Overseas Business Development
Alice Song: Head of International Business Department, Bank of Jiangsu Shanghai Branch

15:05-16:00　Nuts, Bolts and Best Practices of Cross-Border BD and Investment Deals
Jimmy Zhang (Moderator): Executive Mentor, QB3/Bakar Labs, UC Berkeley
Albert Ren: Vice President, Head of WWBD China, Pfizer
John Zhu: Founder, Chairman and CEO of Duality Bio
Chen Ming Yu: Founder & Managing Partner, TCG Crossover
Kevin Guan: Lawyer of Goodwin’s Asia Life Sciences

Jenkins Fung: Head of North Asia ex-Japan at SS&C Intralinks

16:00-16:40　Panel Discussion I: Advancing Global Collaboration for Innovative Medicines: Strategy, Capabilities, and Value Creation
Han Dai (Planner & Moderator): Chief Innovation Officer, Head of Investment & Strategy, Vivarium
Dan Wang: Head of External Scientific Innovation Asia Pacific, Johnson & Johnson
Fred Li: Director, Search & Evaluation, Novartis China
Frank Luo: Associate Vice President, Simcere Zaiming (North America and Europe BD)
Yi Ding: BD Director, RA Swiftbridge
Morgan Xu: Partner, Foley Hoag LLP

16:40-17:30　Panel Discussion II: Reimagining the Biopharma BD Ecosystem: Multi-Stakeholder Collaboration and Emerging Paradigms
Mingde Xia (Moderator): Founder, Chairman & CEO, Innolake Biopharm
Jenny Yang: Head of External Innovation, Asia Pacific, Novo Nordisk A/S
Jian Lin: Senior Director, External Innovation, JNJ
Dong Chen: Executive Director, External Innovation, AbbVie
Betty Huang: VP and Head of Collaborate to Cure Hub China, Bayer Pharmaceuticals
Hao Huang: Head of the New Business for Marketing Solutions, LinkedIn China
Shuai Chen: Deputy General Manager, Overseas Business Department, Bank of Ningbo (NBCB)

July 22 (Afternoon)

Conference Planning / Conference Moderation
Andreas Penk：Co-founder & CEO, EBT; Former President of Pfizer China
Fenping Zhang：Chairman&CEO at genOway Shanghai

12:30-13:40　Dinner Reception

14:00-14:20　Opening Address
Alexandre EA：Head of the Lifestyle and Health Division – China / Hong Kong；Co-president of FHA
Olivier Charmeil：Executive Vice President, Sanofi

14:20-14:35　China efficiency：true or false？
Dan Zhang：Co-founder & CSO Shenzhen GrandBay Medical Consulting Company Ltd; Board Member & Chief Strategic Officer  ClinChoice Medical Development Ltd; Co-Chairman & Co-founder  Hillgene Biopharma Ltd

14:35-14:50　The strategic imperative: partnering in China’s Ecosystem - an MNC perspective
Hong Shen：Head of China Innovation Center of Roche and SVP

14:50-15:05　TBD
Alexandre Fraichard：Founder&CEO at genOway

15:05-15:20　TBD
Jianxin Yang：CEO, Executive Director, President of R&D,  

15:20-16:10　Panel Discussion：How Can European Innovative Medicines Benefit from China's Innovation System? 
Andreas Penk（Moderation）：Co-founder & CEO, EBT; Former President of Pfizer China
Kendra Rose：Senior Vice President and Head of BD&L/OI New Platforms, Cardiovascular and Immunology at Bayer
Lianshan Zhang：EVP&Board member of Jiangsu Hengrui
Harm-Jan Borgeld：Global Head, Asia Partnering at Roche
David Montgomery：co-founders of PM life sciences; Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; CEO of PM Life Sciences
David Montgomery：co-founders of PM life sciences; Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; CEO of PM Life Sciences
Stefan Platz：Senior Vice President Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca
Xiaobin Wu：Global President and COO, BeOne Medicines

16:10-16:25　TBD
Jun Zhu：Executive Director&CEO at Henlius

16:25-16:40　TBD
Elisabeth Liu：Eximium Asia  & Confluence Global Capital CEO

16:40-16:55　TBD
Jenny Yang：Head of External Innovation, Asia Pacific at Novo Nordisk

16:55-17:10　TBD
Xin Xie：Executive Director&SVP of Sino Biopharmaceutical; SVP of CP Group

17:10~18:00　Panel Discussion：Building a Global Innovation Ecosystem Together Through China's New Biopharmaceutical Infrastructure
Fenping Zhang（Moderation）：Chairman&CEO at genOway Shanghai
Yingjie Wu：Executive Director, Search & Evaluate, Business Development, Oncology R&D, AstraZeneca
Lihua Yu：COO&SVP of Wuxibiologics
Jeff Duan：Founder&Chairman at PharmaLegacy
Yan Chang：Chairwomen&President at InnoStar Bio
Xiaoou Xu：Chairman at ClinChoice
Zhi Chen：Chairman at Bio-Link

18:00-21:00　Banquet: Closed-Door Exchange Dinner on Innovative Drug Collaboration and Development — When European Depth Meets Chinese Speed

July 23 (Morning)

09:00-09:20　TBD
Wayne Shi：President, Sanofi Greater China

09:20-09:35　TBD
Benedikt Westphalen：Director of the Center for Personalized
edicine at LMU University Hospital Munich；Head of the recision Oncology Program at the Comprehensive Cancer Center Munich

09:35-09:50　TBD
Andreas Föller：Founder&CEO of Cardea

09:50-09:55　Introduction to the UK Faculty of Pharmaceutical Medicine (FPM)

09:55-10:40　Panel Discussion：Embracing Europe to Accelerate China's Biopharmaceutical Innovation
Huini Li（Moderator）：Partner/Of Counsel at Adaltys Avocats
Salah-Eddin Al-Batran：CEO of the Frankfurt Institute of Clinical Cancer Research (IKF)；Chief Physician at North West Hospital Frankfurt；Board of Directors Member, University Cancer Center Frankfurt, Germany
Edward Jones：CEO of Newmarket Strategy
Ke Shao：Deputy General Manager of Kexing Biopharm
Yaping Shen：Executive President at Hybio
Lijuan Wang：CSO for Chemical Pharmaceuticals at Salubris
Jia Xiao：Sales & Marketing Executive (Life Sciences) at IDA Ireland

10:40-10:55　TBD
Sheuli Porkess：co-founders of PM life sciences;Fellows of the Faculty of Pharmaceutical Medicine (FPM) of the Royal Colleges of Physicians of the UK; President and Chair of the Board of Trustees of the Faculty of Pharmaceutical Medicine；President of the Faculty of Pharmaceutical Medicine from the UK

10:55-11:10　TBD
Bin Li：Distinguished Professor at Shanghai Jiao Tong University
Vice-President of the Shanghai Overseas Returned Scholars Association
Deputy Director of the Shanghai Institute of Immunology

11:10-11:25　TBD
Willy Courtel：CEO of Laboratories Superdiet - URGO Group

11:25-11:40　TBD
Martin Heidecker    ：CIO of AMR Action Fund

11:40-11:55　TBD
Chih-Yi Hsieh：Global Clinical Development, Asia-Pacific Region Vice President at BioNTech

Ms. Jeanne Wang（planner）： Executive Director and Chief Commercial Officer
Mr. Jack Wang（host）：Vice President and Head of International Business, CanSinoBIO

13:30-13:40   Opening Remarks
Mr. Houjia Liu：Director, SCBD

13:40-14:00   Innovation and regulatory pathways for vaccines, biosimilars, and advanced therapies under Brazil's policy framework
Ms. Perla Villani Borges：Head of BD, Bio-MANGUINHOS/FIOCRUZ

14:00-14:20   The European and Gulf Opportunity: A Strategic Blueprint for Chinese Biopharma
Mr. Jerome Cabannes：Pharma and Life Sciences Senior Advisor & Former CEO, SPIMACO & Former COO of AJ Vaccines

14:20-14:40   Innovation Without Borders: How Chinese Biopharma Reaches the World -- Proven on the Eurasian Frontier
Mr. Yaroslav Botsman：BD Director, Petrovax Pharm

14:40-15:30   Panel DIscussion: How Chinese Innovation Can More Effectively Deliver Value to Pharmaceutical Development in BRICS Countries
Ms. Jeanne Wang：  Executive Director and Chief Commercial Officer
Mr. Nathan Tirtana：President Director, PT Etana Biotechnologies

Mr. Andreas Pierotic：Bofill Mir Abogados，Head of China & Asia Affairs Of Counsel
Dato’Mohd Nazlee Kamal：Group Chief Executive Officer, Solution Group Berhad, 

15:30-15:50   Tea Break & Networking

15:50-16:10   The New Silk Road of Biotechnology: How Chinese Innovation Can Shape the Next Global Healthcare Order
Dr. Tabassum Khan：Founder & Chairman, STRATGURUS Group

16:10-16:30   Macro Environment of the Pharmaceutical Industry in Emerging Markets and New Opportunities for BRICS Cooperation
Ms. Jia Xu：China Pharma and Healthcare Industry Leader, PwC

16:30-17:20   Closing Discussion:Co-building Emerging Markets and Value Symbiosis for China's Innovative Drugs
Dr. Xiaobin Wu：President & Chief Operating Officer, BeOne
Dr. Xingli Wang：Co-President, Forsun Pharma
Ms. Cecilia Qi：CEO, DCH Auriga
Mr. Jinqun Yin：VP, Kanghong Pharmaceutical

17:20-17:30   Closing Remarks
Ms. Jeanne Wang：Executive Director and Chief Business Officer, CanSino BIO

Planner:

Yingchun Zhao：Founder, PolyEngine Technologies; Partner, Beijing BioInno Technology; Vice President, SAPA-DC
James Bo：International Institute of Applied Technology (IATRI)

    
13:00-13:10　Opening Remarks: China Innovative Drug Globalization 2.0: Building a New FDA-Ready Industrialization Paradigm
Victor Liang：Partner, Beijing BioInno Technology; Co-founder, Nuraydia Life Sciences

13:10-13:20　From China R&D to FDA IND: The First Gateway to Global Drug Development
Jinhui Dou：Consultant, JP Consulting Group

13:20-13:30　From IND Clearance to Patient Enrollment: Building North American Clinical Development Capabilities
Jane Fang：Founder & CEO, Polaris Strategic Partners

13:30-13:40　From AI Prediction to Real-World Evidence: How AIDD Enables End-to-End Acceleration of FDA-Ready Drug Candidates
Dr. Rico W. Tang：Chief Science Advisor, AIDM

13:40-13:50　AI-Native Clinical Development: Reconstructing the Future Clinical Decision-Making System
Will Ma：Founder & CEO, HopeAI

13:50-14:00　From Data to Decisions: How AI is Transforming Clinical Statistics and Regulatory Deliverables
Oliver Li：Co-founder & Head of Product, Hill Research

14:00-14:10　A New Paradigm for Pharmacovigilance in the FDA Era: Intelligent Safety Monitoring Powered by Knowledge Graphs and Large Language Models
Kaixian Yu：Founder & CEO, MedGraph Intelligence

14:10-14:20　From Patient Navigation to Global Trial Acceleration: How Digital Health is Transforming Clinical Development
Frank Chen：President & CEO, LINKMedicine.AI

14:20-14:30　Innovation and Practice in Nucleic Acid Therapeutics: From Technological Breakthroughs to Commercialization
Shawn Pan：CBO, Cosynbio

14:30-15:20　China Innovative Drug Globalization 2.0: How to Build FDA-Ready North American Industrialization Capabilities?

Victor Liang（Host）：Partner, Beijing BioInno Technology; Co-founder, Nuraydia Life Sciences
Charles Li：Co-founder & CEO, Nuraydia Life Sciences; Partner, Beijing BioInno Technology
Jinhui Dou：Consultant, JP Consulting Group
Jane Fang：Founder & CEO, Polaris Strategic Partners
Will Ma：Founder & CEO, HopeAI
Dr. Rico W. Tang：Chief Science Advisor, AIDM
Oliver Li：Co-founder & Head of Product, Hill Research
Kaixian Yu：Founder & CEO, MedGraph Intelligence
Shawn Pan：CBO, Cosynbio

Special Session Planning
Ke Shao：Deputy General Manager, Kexing Biopharm
Jiali Luo：CEO, TOBIO Group

09:00-09:05　Host Opening
Ke Shao：Deputy General Manager, Kexing Biopharm

09:05-09:25　Investment in China's Biomedical Industry and Future Industrial Trends
Xun Zhu ：Founding Chairman, Tonacea New Drug Talent Club

09:25-09:45　Opportunities and Strategic Choices for Chinese Enterprises Under the New Global Landscape of Biosimilars
Han Bai：Principal, Custom Solutions，APAC Norstella

09:45-10:05　CMC Development and Commercialization of Biosimilars
Jun Ma：Principal, Custom Solutions，APAC Norstella

10:05-10:25　From Followers to Pioneers: Reshaping the Global Biosimilars Landscape
Max Fernandez：VP， Intellective Biologics (Suzhou) Co., Ltd.

10:25-10:45　Opportunities and Challenges of Global Biosimilars: Exploration and Reflections of Kexing Biopharm
Ke Shao：Deputy General Manager, Kexing Biopharm

10:45-11:25　Joint Efforts for Mass Production: Large-Scale Manufacturing and Cost Optimization of Biosimilars
Moderator: Jiali Luo, Ascendis Biologics：CEO of Asymchem Biologics Group
Sheng Zhou: Deputy General Manager of Lisure Technology
More guests are being invited .....

11:25-12:05　Biosimilars Overseas Expansion Roundtable
Ke Shao（host）：Deputy General Manager, Kexing Biopharm
More guests are being invited .....

Meeting Planner
Lawrence HE Lian：Chief Executive Officer, Rxilient
Frank HONG Tan：Managing Director, Legend Capital

09:00-09:15   Opening and Welcome
Frank HONG Tan：Managing Director, Legend Capital

09:15-09:35   Pharmaceutical Opportunities and Development Trends in Emerging Markets
Qicong HU：Managing Director & Partner, Boston Consulting Group (BCG）

09:35-10:05   Globalization Pathways for Innovative Pharmaceutical Companies
Xiaobin WU：President, BeiGene

10:05-10:25   Rxilient's Strategy and Practice in Emerging Markets
Lawrence HE Lian：Chief Executive Officer, Rxilient

10:25-10:50   Tea break

10:50-11:10   Collaboration and Opportunities between Singapore and China's Innovative Pharmaceutical Industry
Zi Tian PHANG：Head of Shanghai Office, Singapore Economic Development Board (EDB)

11:10-12:00   Roundtable: Pharmaceutical Policies in Southeast Asia and Case Studies on Overseas Commercialization
 Brian YANG（Moderator）：Chief Commercial Officer, Rxilient
Qingsong WANG：Founder & Chief Executive Officer, Nanjing Delova Biotech Co., Ltd.
Yifeng JIN：Head of Business Development, Chongqing Genrix Biopharmaceutical Co., Ltd.
Yongping PAN：Chief Business Officer, Etana Biotechnologies

Ricky Teo：Chief Operating Officer, Rxilient

12:00-14:00   Lunch

14:00-14:20   Opportunities, Regulatory Environment and Commercialization Experience in the Middle East Market
Hisham OMAR：General Manager, Middle East & North Africa, Rxilient

14:20-14:40   Clinical Trial Ecosystem in Emerging Markets and Opportunities 
for Chinese Pharmaceutical Companies
Steven NG：Deputy Director, Business Development, ClinChoice

14:40-15:30   Roundtable: Middle East and Latin America – A Multidimensional Dialogue on Cross-Regional Commercialization, Registration, and Investment
Jessie CHEN（Moderator）：Senior Director, Business Development, Rxilient
Hongyi WANG：Vice President, International Business, CanSino Biologics Inc.
Dong WEI：Vice President, Qingfeng Pharmaceutical Group
Nancy TSUI Chung：Head of China Desk, Pinheiro Neto Advogados
Steven NG：Deputy Director, Business Development, ClinChoice
Hisham OMAR：General Manager, Middle East & North Africa, Rxilient

15:30-16:00  Tea break

16:00-16:20   Investment Strategies and Deployment in Emerging Markets for Pharmaceuticals
Frank HONG Tan：Managing Director, Legend Capital

16:20-17:10   Roundtable: Investment Opportunities in Emerging Markets from a Capital Perspective
Fei QI（Moderator）：Executive Director, Legend Capital
Xiaohui ZHANG：Deputy Director, China Chamber of Commerce for Import & Export 
of Medicines and Health Products
Yao WU：Director, Private Equity, Silk Road Fund
Xuanhe WANG：Investment Officer, Asian Infrastructure Investment Bank (AIIB)
Sylvia ZHOU：Investment Director, True Light Capital
Jin ZHANG：Executive General Manager, Research Department, China International Capital Corporation Limited (CICC)

17:10-17:20   Closing Remarks
Lawrence HE Lian：Chief Executive Officer, Rxilient